© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Manali A. Bhave, MD, is an assistant professor in the department of hematology and medical oncology at Emory University School of Medicine.
June 01, 2022
Physicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.
March 07, 2022
Manali Bhave, MD, discusses the updated results of the MonarchE study of abemaciclib in patients with hormone receptor-positive, HER2-negative, breast cancer.